Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 2
1984 1
1985 2
1987 2
1988 1
1989 5
1990 5
1991 5
1992 3
1993 5
1994 7
1995 5
1996 3
1997 3
1998 5
1999 6
2000 4
2001 10
2002 10
2003 3
2004 8
2005 9
2006 6
2007 4
2008 2
2009 2
2011 11
2012 4
2013 2
2014 8
2015 10
2016 4
2017 4
2018 4
2019 8
2020 3
2021 4
2022 5
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Results by year

Filters applied: . Clear all
Page 1
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia.
Staber PB, Herling M, Bellido M, Jacobsen ED, Davids MS, Kadia TM, Shustov A, Tournilhac O, Bachy E, Zaja F, Porkka K, Hoermann G, Simonitsch-Klupp I, Haferlach C, Kubicek S, Mayerhoefer ME, Hopfinger G, Jaeger U, Dearden C. Staber PB, et al. Blood. 2019 Oct 3;134(14):1132-1143. doi: 10.1182/blood.2019000402. Epub 2019 Jul 10. Blood. 2019. PMID: 31292114 Free PMC article. Review.
T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. ...
T-cell prolymphocytic leukemia (T-PLL) is a rare, mature T-cell neoplasm with a heterogeneous clinical course. ...
T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.
Gutierrez M, Bladek P, Goksu B, Murga-Zamalloa C, Bixby D, Wilcox R. Gutierrez M, et al. Int J Mol Sci. 2023 Jul 28;24(15):12106. doi: 10.3390/ijms241512106. Int J Mol Sci. 2023. PMID: 37569479 Free PMC article. Review.
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells. ...
T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive neoplasm of mature T-cells. ...
Prolymphocytic leukemias.
Krishnan B, Matutes E, Dearden C. Krishnan B, et al. Semin Oncol. 2006 Apr;33(2):257-63. doi: 10.1053/j.seminoncol.2006.01.015. Semin Oncol. 2006. PMID: 16616073 Review.
T-cell prolymphocytic leukemia.
Khot A, Dearden C. Khot A, et al. Expert Rev Anticancer Ther. 2009 Mar;9(3):365-71. doi: 10.1586/14737140.9.3.365. Expert Rev Anticancer Ther. 2009. PMID: 19275513 Review.
T-cell prolymphocytic leukemia is a rare post-thymic lymphoid disorder, which has distinctive clinical, morphologic, immunophenotypic and cytogenetic features. ...
T-cell prolymphocytic leukemia is a rare post-thymic lymphoid disorder, which has distinctive clinical, morphologic, immunophe …
T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases.
Hu Z, Medeiros LJ, Xu M, Yuan J, Peker D, Shao L, Tang Z, Mai B, Thakral B, Rios A, Hu S, Wang W. Hu Z, et al. Am J Clin Pathol. 2023 Apr 4;159(4):325-336. doi: 10.1093/ajcp/aqac166. Am J Clin Pathol. 2023. PMID: 36883805
OBJECTIVES: T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell leukemia usually characterized by inv(14)(q11.2q32)/t(14;14)(q11.2;q32). ...
OBJECTIVES: T-cell prolymphocytic leukemia (T-PLL) is a rare mature T-cell leukemia usually characterized by inv(14)(q11.2q32) …
Delineation of clinical course, outcomes, and prognostic factors in patients with T-cell prolymphocytic leukemia.
Rose A, Zhang L, Jain AG, Poovathukaran Babu A, Sokol L, Saeed H, Mo Q, Fan W, Zhang X. Rose A, et al. Am J Hematol. 2023 Jun;98(6):913-921. doi: 10.1002/ajh.26918. Epub 2023 Apr 3. Am J Hematol. 2023. PMID: 36964941
T-cell prolymphocytic leukemia (T-PLL) is a rare, post-thymic T-cell neoplasm with a diverse clinical course. ...
T-cell prolymphocytic leukemia (T-PLL) is a rare, post-thymic T-cell neoplasm with a diverse clinical course. ...
T-small lymphocyte disorders.
Bartlett NL, Longo DL. Bartlett NL, et al. Semin Hematol. 1999 Apr;36(2):164-70. Semin Hematol. 1999. PMID: 10319385 Review.
Less than 2% of all lymphoproliferative diseases are indolent or small T-cell disorders, and include T-cell chronic lymphocytic leukemia (CLL)/prolymphocytic leukemia (PLL), large granular lymphocyte (LGL) leukemia, and mycosis fungoides (MF). ...
Less than 2% of all lymphoproliferative diseases are indolent or small T-cell disorders, and include T-cell chronic lymphocytic leukemia (CL …
Minimal residual disease.
Radich J. Radich J. Curr Opin Hematol. 1995 Jul;2(4):300-4. doi: 10.1097/00062752-199502040-00010. Curr Opin Hematol. 1995. PMID: 9372011 Review.
It has become clear that the mere detection of minimal residual disease does not foretell relapse; thus, although the presence of minimal residual disease in acute lymphoblastic leukemia and acute prolymphocytic leukemia appears to be associated with a high risk of …
It has become clear that the mere detection of minimal residual disease does not foretell relapse; thus, although the presence of minimal re …
Alemtuzumab (Millennium/ILEX).
Dumont FJ. Dumont FJ. Curr Opin Investig Drugs. 2001 Jan;2(1):139-60. Curr Opin Investig Drugs. 2001. PMID: 11527007
In April 1997, LeukoSite licensed rights to the antibody from BTG for the treatment of CLL and prolymphocytic leukemia, plus an option to develop it for other indications. ...
In April 1997, LeukoSite licensed rights to the antibody from BTG for the treatment of CLL and prolymphocytic leukemia, plus a …
178 results